A novel Trojan-horse targeting strategy to reduce the non-specific uptake of nanocarriers by non-cancerous cells

	A novel Trojan-horse targeting strategy to reduce the non-specific uptake of nanocarriers by non-cancerous cells
	Shen, Zheyu 1; Wu, Hao 2; Yang, Sugeun 3; Ma, Xuehua 1; Li, Zihou 1; Tan, Mingqian 2; Wu, Aiguo 1
刊名	biomaterials
	2015-11-01
卷号	70 页码:1-11
关键词	Trojan-horse targeting strategy MRI contrast agents Active targetability to cancer cells Non-specific uptake by non-cancerous cells
英文摘要	one big challenge with active targeting of nanocarriers is non-specific binding between targeting molecules and non-target moieties expressed on non-cancerous cells, which leads to non-specific uptake of nanocarriers by non-cancerous cells. here, we propose a novel trojan-horse targeting strategy to hide or expose the targeting molecules of nanocarriers on-demand. the non-specific uptake by non-cancerous cells can be reduced because the targeting molecules are hidden in hydrophilic polymers. the nanocarriers are still actively targetable to cancer cells because the targeting molecules can be exposed on-demand at tumor regions. typically, fe3o4 nanocrystals (fn) as magnetic resonance imaging (mm) contrast agents were encapsulated into albumin nanopartides (an), and then folic acid (fa) and ph-sensitive polymers (pp) were grafted onto the surface of an-fn to construct pp-fa-an-fn nanoparticles. fourier transform infrared spectroscopy (ft-ir), dynamic light scattering (dls), transmission electron microscope (tem) and gel permeation chromatography (gpc) results confirm successful construction of pp-fa-an-fn. according to difference of nanoparticle-cellular uptake between ph 7.4 and 5.5, the weight ratio of conjugated pp to nanoparticle fa-an-fn (i.e. graft density) and the molecular weight of pp (i.e. graft length) are optimized to be 132 and 5.7 kda, respectively. in vitro studies confirm that the pp can hide ligand fa to prevent it from binding to cells with fr alpha at ph 7.4 and shrink to expose fa at ph 5.5. in vivo studies demonstrate that our trojan-horse targeting strategy can reduce the nonspecific uptake of the pp-fa-an-fn by non-cancerous cells. therefore, our pp-fa-an-fn might be used as an accurately targeted mri contrast agent. (c) 2015 elsevier ltd. all rights reserved.
WOS标题词	science & technology ; technology
类目[WOS]	engineering, biomedical ; materials science, biomaterials
研究领域[WOS]	engineering ; materials science
关键词[WOS]	iron-oxide nanoparticles ; mri contrast agent ; drug-delivery ; cancer-therapy ; in-vivo ; n-isopropylacrylamide ; polymeric micelle ; anticancer drug ; liver-cancer ; ph
收录类别	SCI
语种	英语
WOS记录号	WOS:000362610600001
公开日期	2016-05-09
内容类型	期刊论文
源URL	[http://cas-ir.dicp.ac.cn/handle/321008/146591]
专题	大连化学物理研究所_中国科学院大连化学物理研究所
作者单位	1.Chinese Acad Sci, Ningbo Inst Mat Technol & Engn, Div Funct Mat & Nano Devices, Key Lab Magnet Mat & Devices, Ningbo 315201, Zhejiang, Peoples R China 2.Chinese Acad Sci, Dalian Inst Chem Phys, Div Biotechnol, Dalian 116023, Peoples R China 3.Inha Univ, Sch Med, Dept New Drug Dev, Inchon 400712, South Korea
推荐引用方式 GB/T 7714	Shen, Zheyu,Wu, Hao,Yang, Sugeun,et al. A novel Trojan-horse targeting strategy to reduce the non-specific uptake of nanocarriers by non-cancerous cells[J]. biomaterials,2015,70:1-11.
APA	Shen, Zheyu.,Wu, Hao.,Yang, Sugeun.,Ma, Xuehua.,Li, Zihou.,...&Wu, Aiguo.(2015).A novel Trojan-horse targeting strategy to reduce the non-specific uptake of nanocarriers by non-cancerous cells.biomaterials,70,1-11.
MLA	Shen, Zheyu,et al."A novel Trojan-horse targeting strategy to reduce the non-specific uptake of nanocarriers by non-cancerous cells".biomaterials 70(2015):1-11.